{"id":744813,"date":"2023-04-03T16:03:22","date_gmt":"2023-04-03T20:03:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\/"},"modified":"2023-04-03T16:03:22","modified_gmt":"2023-04-03T20:03:22","slug":"cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\/","title":{"rendered":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SOUTH SAN FRANCISCO, Calif., April  03, 2023  (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 31, 2023 it granted stock options to purchase an aggregate of 57,600 shares of common stock to 4 new employees, whose employment commenced in March 2023, as a material inducement to their employment.<\/p>\n<p align=\"justify\">The stock options that were granted are subject to an exercise price of $35.19 per share, which is equal to the closing price of the Company\u2019s common stock on March 31, 2023, and will vest over 4 years, with 1\/4<sup>th<\/sup> of the shares underlying the employee\u2019s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1\/48<sup>th<\/sup> of the shares underlying each employee\u2019s option over the subsequent 36 months, subject to the new employee\u2019s continued service with the Company. Each stock option has a 10-year term and is subject to the terms and conditions of the Company&#8217;s Amended and Restated 2004 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.<\/p>\n<p align=\"justify\">The options were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p align=\"justify\">\n        <strong>About Cytokinetics <\/strong>\n      <\/p>\n<p align=\"justify\">Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is developing <em>aficamten<\/em>, a next-in-class cardiac myosin inhibitor, currently the subject of SEQUOIA-HCM, the Phase 3 clinical trial of <em>aficamten<\/em> in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). <em>Aficamten<\/em> is also being evaluated in non-obstructive HCM and the company plans to begin a Phase 3 trial later this year. Cytokinetics is also developing <em>omecamtiv mecarbil<\/em>, a cardiac muscle activator in patients with heart failure. In 2023, Cytokinetics is celebrating its 25-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.<\/p>\n<p align=\"justify\">For additional information about Cytokinetics, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XJzsVU1cFi0h1g3req67CfF8KnSxPM_Oc4-RVrtJCRBynIWDCU4qVGdxPbEJ3FoyTPisMH8g74AuUVaU8ddOPqXvcEuQTcu9_5TrohTAUJs=\" rel=\"nofollow noopener\" target=\"_blank\">www.cytokinetics.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hUbNJf2OY4ZzorSF18dPISToyEY199vvxLFa89WA2bjmbyC6ge---5zmvDhsCbIk4d20Jd31FcVM83O6BCNoqg==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_RzLNqXFh8cIiMbuIzCrxgDe-p1Q_KNqmUN18wBQxlxegTQ7s2hs9kV2u1hdOnoLvBaLuu5SnhFYKL128AmKnK-UjgWeqc_pssMMogSI1k8=\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DJUBpfmZT3CUHrXQqvC1aRiS3xdDL_UDgL-C-CjAmsRlnQFQvLCMazKsc8Ei97XUt1UK8vwxY4kabrrOyzwwd4HvhM2Vk13Lpl4crXSxsSw=\" rel=\"nofollow noopener\" target=\"_blank\">Facebook<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Mdjxoivx_8Uc8RfS6Sb1I8LwJ_6ZYB9BnlS3wZmYmcIlF7eEVUsh5X5BNEzZft9wOE6gcXOjx7Q_Tact3OP_FWwB2rXwgKVTuuUAGq0-MflBd7utVGjBWbqAtwBeQcga\" rel=\"nofollow noopener\" target=\"_blank\">YouTube<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the &#8220;Act&#8221;).\u00a0Cytokinetics\u00a0disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act&#8217;s\u00a0Safe Harbor\u00a0for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to\u00a0Cytokinetics&#8217;\u00a0and its partners&#8217; research and development activities of Cytokinetics\u2019 product candidates. Such statements are based on management&#8217;s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to\u00a0Cytokinetics&#8217;\u00a0business outlined in\u00a0Cytokinetics&#8217;\u00a0filings with the\u00a0Securities and Exchange Commission particularly under the caption \u201cRisk Factors\u201d in Cytokinetics\u2019 latest Quarterly Report on Form 10-Q. Forward-looking statements are not guarantees of future performance, and\u00a0Cytokinetics&#8217;\u00a0actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that\u00a0Cytokinetics\u00a0makes in this press release speak only as of the date of this press release.\u00a0Cytokinetics\u00a0assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n<p align=\"justify\">CYTOKINETICS\u00ae and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.<\/p>\n<p align=\"justify\">Contact:<br \/>Cytokinetics <br \/>Diane Weiser<br \/>Senior Vice President, Corporate Communications, Investor Relations<br \/>(415) 290-7757<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTEwOCM1NTA2OTA5IzIwMDUxMDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MzZhZGVlYTctZWYyZi00MzY4LWJhOTItYTczYjNhOTg0Mzc4LTEwMTY2NzY=\/tiny\/Cytokinetics-Incorporated.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., April 03, 2023 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 31, 2023 it granted stock options to purchase an aggregate of 57,600 shares of common stock to 4 new employees, whose employment commenced in March 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $35.19 per share, which is equal to the closing price of the Company\u2019s common stock on March 31, 2023, and will vest over 4 years, with 1\/4th of the shares underlying the employee\u2019s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-744813","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., April 03, 2023 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 31, 2023 it granted stock options to purchase an aggregate of 57,600 shares of common stock to 4 new employees, whose employment commenced in March 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $35.19 per share, which is equal to the closing price of the Company\u2019s common stock on March 31, 2023, and will vest over 4 years, with 1\/4th of the shares underlying the employee\u2019s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate &hellip; Continue reading &quot;Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-03T20:03:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTEwOCM1NTA2OTA5IzIwMDUxMDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2023-04-03T20:03:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\\\/\"},\"wordCount\":607,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMTEwOCM1NTA2OTA5IzIwMDUxMDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\\\/\",\"name\":\"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMTEwOCM1NTA2OTA5IzIwMDUxMDM=\",\"datePublished\":\"2023-04-03T20:03:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMTEwOCM1NTA2OTA5IzIwMDUxMDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMTEwOCM1NTA2OTA5IzIwMDUxMDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\/","og_locale":"en_US","og_type":"article","og_title":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., April 03, 2023 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 31, 2023 it granted stock options to purchase an aggregate of 57,600 shares of common stock to 4 new employees, whose employment commenced in March 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $35.19 per share, which is equal to the closing price of the Company\u2019s common stock on March 31, 2023, and will vest over 4 years, with 1\/4th of the shares underlying the employee\u2019s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate &hellip; Continue reading \"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-03T20:03:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTEwOCM1NTA2OTA5IzIwMDUxMDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2023-04-03T20:03:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\/"},"wordCount":607,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTEwOCM1NTA2OTA5IzIwMDUxMDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\/","name":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTEwOCM1NTA2OTA5IzIwMDUxMDM=","datePublished":"2023-04-03T20:03:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTEwOCM1NTA2OTA5IzIwMDUxMDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMTEwOCM1NTA2OTA5IzIwMDUxMDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-23\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/744813","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=744813"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/744813\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=744813"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=744813"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=744813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}